Trial Profile
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms PATHFINDER 3
- Sponsors Novo Nordisk; Novo Nordisk Pharma
- 01 Jan 2022 Post hoc analysis was performed by applying datamining techniques retrospectively to the final results of the pathfinder 2 and 3 clinical trials and analysing the resulting data descriptively; results published in the Haemophilia
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology
- 20 Jun 2019 According to a Novo Nordisk media release, the European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents (=12 years of age) and adults with haemophilia A.